Evaluation of Ki-67 monoclonal antibody as prognostic indicator for prostatic carcinoma.
Prostate tissue containing either primary adenocarcinoma (45 patients) or benign hyperplasia (15 patients) was immunostained with the monoclonal antibody Ki-67, which recognises a human nuclear antigen expressed by human cycling cells. The percentage of cells staining positive was considered a measure of proliferation. This derived Ki-67 index was higher for carcinomas than for hyperplastic glands. Within the group of carcinomas, Ki-67 indices in patients with metastatic disease were significantly higher than in those without and there was a trend towards increasing Ki-67 indices with increasing Gleason grade. When patients with prostate cancer were prospectively followed up, the Ki-67 index did not predict either disease progression or hormone responsiveness. Ki-67 immunostaining may define a group of patients with prostate cancer of poor prognosis.
McLoughlin
J
J
Department of Surgery, Royal Postgraduate Medical School, Hammersmith Hospital, London.
Foster
C S
CS
Price
P
P
Williams
G
G
Abel
P D
PD
D000230:Adenocarcinoma / Q000175:diagnosis / Q000473:pathology* / Q000556:secondary / Q000628:therapy; D000368:Aged; D000369:Aged, 80 and over; D000911:Antibodies, Monoclonal; D000951:Antigens, Neoplasm / Q000032:analysis* / Q000276:immunology; D002455:Cell Division; D006801:Humans; D008297:Male; D008875:Middle Aged; D009687:Nuclear Proteins / Q000032:analysis* / Q000276:immunology; D011379:Prognosis; D011470:Prostatic Hyperplasia / Q000175:diagnosis / Q000473:pathology; D011471:Prostatic Neoplasms / Q000175:diagnosis / Q000473:pathology* / Q000628:therapy
D000911:Antibodies, Monoclonal; D000951:Antigens, Neoplasm; D009687:Nuclear Proteins